Commodore Capital LP 13F holdings, Q4 2025
Holdings as of December 31, 2025 · filings on SEC EDGAR · latest filing →
Commodore Capital LP disclosed 33 US equity positions worth $1.5bn in its Q4 2025 13F filing. The largest position was RLAY at 9.6% of the reported book, followed by ALKS and TYRA. Against the Q3 2025 filing, it opened 6 new positions, added to 4 and reduced 12 among the top 33 holdings.
What did Commodore Capital LP own in Q4 2025? Top 33 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2025 |
|---|---|---|---|---|---|---|---|
| 1 | RLAY RELAY THERAPEUTICS INC | Healthcare | 9.6% | $143.8m | 17,000,000 | 0% | held |
| 2 | ALKS ALKERMES PLC | Healthcare | 6.6% | $99.3m | 3,550,000 | 15% | added |
| 3 | TYRA TYRA BIOSCIENCES INC | Healthcare | 5.9% | $88.7m | 3,375,000 | 0% | held |
| 4 | XENE XENON PHARMACEUTICALS INC | Healthcare | 5.4% | $80.7m | 1,800,000 | -33% | reduced |
| 5 | SYRE SPYRE THERAPEUTICS INC | 5.2% | $78.2m | 2,388,245 | 20% | added | |
| 6 | COGT COGENT BIOSCIENCES INC | Healthcare | 5.2% | $78.0m | 2,196,845 | -70% | reduced |
| 7 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 4.8% | $72.3m | 4,692,809 | 0% | held |
| 8 | CLDX CELLDEX THERAPEUTICS INC NEW | Healthcare | 4.6% | $69.7m | 2,565,000 | -15% | reduced |
| 9 | AMLX AMYLYX PHARMACEUTICALS INC | Healthcare | 4.5% | $68.3m | 5,650,000 | 39% | added |
| 10 | 430 TERNS PHARMACEUTICALS INC | 4.0% | $59.6m | 1,475,000 | -74% | reduced | |
| 11 | KYMR KYMERA THERAPEUTICS INC | Healthcare | 3.9% | $58.4m | 750,000 | 0% | held |
| 12 | SLNOEUR SOLENO THERAPEUTICS INC | 3.7% | $55.6m | 1,200,000 | -11% | reduced | |
| 13 | NUVALENT INC | 3.7% | $55.3m | 550,000 | -61% | reduced | |
| 14 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 3.5% | $53.1m | 1,753,054 | 0% | held |
| 15 | PHVS PHARVARIS N V | 3.5% | $52.4m | 1,889,445 | -22% | reduced | |
| 16 | NRIX NURIX THERAPEUTICS INC | Healthcare | 2.9% | $43.2m | 2,275,000 | -40% | reduced |
| 17 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 2.6% | $39.3m | 450,000 | -56% | reduced |
| 18 | ASMB ASSEMBLY BIOSCIENCES INC | Healthcare | 2.3% | $34.0m | 1,000,000 | 0% | held |
| 19 | LB PHARMACEUTICALS INC | 2.2% | $33.4m | 1,500,000 | 0% | held | |
| 20 | CTMX CYTOMX THERAPEUTICS INC | Healthcare | 2.2% | $32.8m | 7,692,300 | 0% | held |
| 21 | ANRO ALTO NEUROSCIENCE INC | Healthcare | 2.2% | $32.5m | 1,823,196 | – | new |
| 22 | PALI PALISADE BIO INC | Healthcare | 1.8% | $26.9m | 11,445,000 | – | new |
| 23 | BRD1EUR MIND MEDICINE MINDMED INC | 1.8% | $26.8m | 2,000,000 | -38% | reduced | |
| 24 | CNTA CENTESSA PHARMACEUTICALS PLC | 1.7% | $25.0m | 1,000,000 | -65% | reduced | |
| 25 | PEPG PEPGEN INC | Healthcare | 1.5% | $22.1m | 3,400,000 | 44% | added |
| 26 | SABS SAB BIOTHERAPEUTICS INC | 1.1% | $16.5m | 4,401,500 | 0% | held | |
| 27 | REPL REPLIMUNE GROUP INC | Healthcare | 0.9% | $13.9m | 1,425,000 | – | new |
| 28 | IKT INHIBIKASE THERAPEUTICS INC | 0.7% | $11.1m | 5,397,488 | 0% | held | |
| 29 | CTNM CONTINEUM THERAPEUTICS INC | 0.6% | $9.3m | 816,326 | – | new | |
| 30 | AVTX AVALO THERAPEUTICS INC | Healthcare | 0.6% | $8.8m | 483,000 | 0% | held |
| 31 | RAPT RAPT THERAPEUTICS INC | 0.6% | $8.5m | 250,000 | – | new | |
| 32 | LONA ATHIRA PHARMA INC | 0.2% | $3.5m | 464,398 | – | new | |
| 33 | DRUG BRIGHT MINDS BIOSCIENCES INC | Healthcare | 0.1% | $1.5m | 18,851 | -96% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.